Author

Meng Xu

Institutions: Beihua University, Jilin Medical University, Beijing Proteome Research Center

Observed institutions: Tongji University, Beihua University, Chinese PLA General Hospital, Jilin Medical University, Beijing Proteome Research Center

ORCID: 0009-0006-0915-6054

Observed ORCID: 0009-0006-0915-6054

OpenAlex ID: A5034240679

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma

2023 · Dongquan Xiang, Xinli Han, et al. · Materials Today Bio · 44

ROS responsive nanoparticles mediated inhibition of monocarboxylic acid transporters to enhance chemoimmunotherapy by overcoming low immune response in osteosarcoma

2023 · Xinli Han, Dongquan Xiang, et al. · Nano Today · 26

20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-XL and MCL-1

2025 · Meng Xu, Feng Hao, et al. · Frontiers in Pharmacology · 5

Gp93 inhibits unfolded protein response‐mediated c‐Jun N‐terminal kinase activation and cell invasion

2024 · Meng Xu, Zhihan Wu, et al. · Journal of Cellular Physiology · 2

Precision medicine research on chemo-immunotherapy combination treatment for locally advanced or metastatic non-small cell lung cancer based on deep plasma proteomics.

2025 · Qiuchi Chen, Qiaoyun Tan, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 77

H-index: 3

I10-index: 2